Avestar Capital LLC Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Avestar Capital LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 787 shares of the biopharmaceutical company’s stock after purchasing an additional 64 shares during the quarter. Avestar Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $561,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Creative Planning raised its stake in Regeneron Pharmaceuticals by 22.7% in the 3rd quarter. Creative Planning now owns 11,793 shares of the biopharmaceutical company’s stock worth $12,397,000 after acquiring an additional 2,178 shares during the last quarter. Bfsg LLC increased its holdings in shares of Regeneron Pharmaceuticals by 3,352.0% in the third quarter. Bfsg LLC now owns 863 shares of the biopharmaceutical company’s stock valued at $907,000 after purchasing an additional 838 shares during the period. Tamar Securities LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 16.6% during the third quarter. Tamar Securities LLC now owns 15,492 shares of the biopharmaceutical company’s stock worth $16,286,000 after purchasing an additional 2,211 shares during the period. Greater Midwest Financial Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 0.7% during the third quarter. Greater Midwest Financial Group LLC now owns 2,520 shares of the biopharmaceutical company’s stock worth $2,649,000 after purchasing an additional 18 shares during the period. Finally, Good Life Advisors LLC boosted its position in Regeneron Pharmaceuticals by 60.0% in the third quarter. Good Life Advisors LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $404,000 after buying an additional 144 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.6 %

REGN stock opened at $674.27 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a 50-day simple moving average of $710.88 and a 200-day simple moving average of $901.80. The stock has a market capitalization of $74.10 billion, a P/E ratio of 17.61, a P/E/G ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the previous year, the firm posted $11.86 EPS. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.52%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Analysts Set New Price Targets

A number of research firms have issued reports on REGN. Citigroup reduced their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Robert W. Baird reduced their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Evercore ISI cut their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.